DARTISLA ODT Drug Patent Profile
✉ Email this page to a colleague
When do Dartisla Odt patents expire, and when can generic versions of Dartisla Odt launch?
Dartisla Odt is a drug marketed by Edenbridge Pharms and is included in one NDA.
The generic ingredient in DARTISLA ODT is glycopyrrolate. There are seventeen drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dartisla Odt
A generic version of DARTISLA ODT was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DARTISLA ODT?
- What are the global sales for DARTISLA ODT?
- What is Average Wholesale Price for DARTISLA ODT?
Summary for DARTISLA ODT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in DARTISLA ODT? | DARTISLA ODT excipients list |
| DailyMed Link: | DARTISLA ODT at DailyMed |
Pharmacology for DARTISLA ODT
| Drug Class | Anticholinergic |
| Mechanism of Action | Cholinergic Antagonists |
US Patents and Regulatory Information for DARTISLA ODT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Edenbridge Pharms | DARTISLA ODT | glycopyrrolate | TABLET, ORALLY DISINTEGRATING;ORAL | 215019-002 | Oct 11, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Edenbridge Pharms | DARTISLA ODT | glycopyrrolate | TABLET, ORALLY DISINTEGRATING;ORAL | 215019-001 | Dec 16, 2021 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
